1. Home
  2. VCIG vs GANX Comparison

VCIG vs GANX Comparison

Compare VCIG & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VCI Global Limited

VCIG

VCI Global Limited

N/A

Current Price

$1.49

Market Cap

1.7M

ML Signal

N/A

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

N/A

Current Price

$1.72

Market Cap

76.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VCIG
GANX
Founded
2013
2017
Country
Malaysia
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7M
76.8M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
VCIG
GANX
Price
$1.49
$1.72
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
★ $7.20
AVG Volume (30 Days)
32.7K
★ 374.5K
Earning Date
10-06-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 31.46
EPS
★ N/A
N/A
Revenue
N/A
★ $55,180.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.81
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.20
$1.53
52 Week High
$23.40
$4.34

Technical Indicators

Market Signals
Indicator
VCIG
GANX
Relative Strength Index (RSI) 47.39 44.56
Support Level $1.54 $1.71
Resistance Level $1.82 $1.85
Average True Range (ATR) 0.11 0.09
MACD -0.04 -0.01
Stochastic Oscillator 3.85 34.82

Price Performance

Historical Comparison
VCIG
GANX

About VCIG VCI Global Limited

VCI Global Ltd is a holding company. The principal activities of the Company and its subsidiaries are the provision of business Strategy consultancy and technology development. The firm organized its consulting services into three main segments: Business Strategy Consultancy; Technology development, solutions and consultancy; and Others. It derives the majority of its revenue from the Business Strategy Consultancy segment, which focuses on listing solutions, investor relations, and boardroom strategies consultancy.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.

Share on Social Networks: